Navigation Links
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients

Encouraging Results Prompted Phase 2 Study Now Underway at Nine Centers

SAN DIEGO, Calif., April 16, 2007 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today presented long term follow-up data from a Phase 1 clinical trial of CERE-120, a gene therapy product in development for the treatment of Parkinson's disease, demonstrating a 36 percent (p<0.001) reduction in Parkinson's symptoms at 12 months after administration, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 was also shown to be well tolerated in this study. The 12-month results were presented today by Philip Starr, M.D., Ph.D., associate professor of neurosurgery at the University of California, San Francisco at the American Association of Neurological Surgeons (AANS) annual meeting in Washington D.C. These data were also highlighted by the AANS in a specific CERE-120 press release issued by the Association.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco and Rush University Medical Center in Chicago. All 12 patients enrolled in the study underwent stereotactic neurosurgery to deliver CERE-120 into their putamen -- a region of the brain affected by the degeneration of neurons in Parkinson's disease.

CERE-120 was delivered at two different doses, and patients receiving the low dose demonstrated approximately 36 percent improvement in UPDRS motor "off" scores by nine months and patients receiving the four-fold higher dose showed a similar effect three months sooner. This statistically significant, 36 percent improvement was maintained in both groups at the 12-month mark, the final follow-up time point in the study. Patients also demonstrated a 50 percent reduction in hours of "
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:10/9/2008)... Day 2008 focuses on the need to protect the eyesi.../ -- Of the 45 million people worldwide who,are bl...s of them could,have avoided their blindness if th...ew the Multimedia News Release, go to:, http://www...ld,s leader in eye care products and equipment, is...
(Date:10/9/2008)...October 9 /- Diamyd Medical... journal, the New England Journal,of Medicine, has...y,s study,of the Diamyd(R) diabetes vaccine for ty...i-bin/prnh/20080314/297194 ), The article is now...nejm.org ) and will be in print on October 30. It ...
(Date:10/8/2008)...rt Institute Pioneers Research That May Offer New ...- Nationally, over 3,000 people are,w... life. Sadly, only half,of those will receive a tr...t Institute (AHI) is paving the way for how to tre...iew the Multimedia News Release, go to:, http://ww...
(Date:10/8/2008)...ngs Confirm Potency of Poly-ICR as Vaccine Adjuvan...enta Biopharmaceuticals,Corporation (TSX: NVN) tod...s using its proprietary Toll-like Receptor 3 agoni... Vaccine Congress 2008 in Lyon, France.,Study resu...djuvant,targeting the Toll-like Receptor 3 (TLR3) ...
Breaking Medicine Technology:ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 1NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 2NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 3NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 4NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 5NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 6NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4620 7The Scooter Store to Provide Power Mobility Equipment to HealthPlus of Michigan Patients 4616 1The Scooter Store to Provide Power Mobility Equipment to HealthPlus of Michigan Patients 4616 2The Scooter Store to Provide Power Mobility Equipment to HealthPlus of Michigan Patients 4616 3Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 1Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 2Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 3Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 4Bayer Issues Additional Guidance to Physicians on Trasylol 28R 29 663 5Brain Region Tied to Amphetamine Addiction 4613 1Brain Region Tied to Amphetamine Addiction 4613 2
...wswire/ -- Mersana, a,cancer therapeutics company,...es with its lead product candidate, XMT-1001, will...eting of the,American Association of Cancer Resear...s, CA. Full text of the abstracts can be,viewed on...f=,"http://www.aacr.org/">http://www.AACR.org . , ...
...the risk of cancer,returning after surgery for Kit... * Patients receiving placebo in this trial will n...ions planned for use of Glivec as,adjuvant therapy...ary tumor , * Glivec already approved as effective...inoperable Kit-positive GIST , BASEL, Switzerland,...
Other Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
(Date:10/11/2008)... MegaFest International Transcends Cultural D...wswire/ -- South African and,international audienc...national,s electrifying gathering, which for the f...ica., (Photo: http://www.newscom.com/cgi-bin/prn...y festival kicked off with performances by,South A...
(Date:10/10/2008)...likely to develop some form of disease by 20 years... Oct. 10 (HealthDay News) -- Liver transplant pati...neral population, say researchers in Finland. ,... Liver Transplantation , researchers investigated...splant recipients from Helsinki University Central...
(Date:10/10/2008)...Lilly and Company committed to helping people addr...re-FirstCall/ -- In these troubling,economic times...priority,and may feel that they don,t have the mon...ccording to a survey by the National Association o...t 2008:(1), -- Twenty-two percent of Americans sa...
(Date:10/10/2008)...FORD, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Hol...manufacturer and supplier of premium,diagnostics, ...cated to,serving the healthcare needs of women, to...and fiscal 2008 operating results on Tuesday, Nove...ith the release, management will,host a conference...
Breaking Medicine News(10 mins):Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2
...ty British cruise vessel, Funchal that has been ar...off the West Australian coast, and will host the m...ngers on board have been infected by a contagious ...municable Disease Control, Dr. Paul Van Buynder sa...
...dex as a tool and indicator of diet is being quest...s. High-GI foods, like white bread and potatoes, t...ome studies have suggested that diets heavy in suc...eight gain, diabetes and heart disease. Still, a d...
...radesh, which has been facing the death of a large...ted the authorities, who in turn has started inves... flu. Suraj Damor, the district magistrate of Burh...in poultry farms at Ichhapur village. Other repor...
...l LWT - Food Science and Technology say that consu...imer’s disease. // Ho Jin Heo and Chang Yong Lee ...nd that red cabbage extract could significantly re...deposits that scientists believe attribute to the ...
Other Medicine News:Health News:Bird Flu Fear Grips Madhya Pradesh 2
Barraquer needle holder, curved, delicate.
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Yasargil Spring Hool with Bulldog Clamp, Galea hook.
Extremely fine straight.
Medicine Products: